These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29378179)

  • 1. Human GIP(3-30)NH
    Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
    Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GIP(3-30)NH
    Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
    Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
    Hansen LS; Sparre-Ulrich AH; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Mar; 173(5):826-38. PubMed ID: 26572091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor.
    Yuliantie E; van der Velden WJC; Labroska V; Dai A; Zhao F; Darbalaei S; Deganutti G; Xu T; Zhou Q; Yang D; Rosenkilde MM; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2021 Oct; 192():114715. PubMed ID: 34339714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge.
    Gasbjerg LS; Rasmussen RS; Dragan A; Lindquist P; Melchiorsen JU; Stepniewski TM; Schiellerup S; Tordrup EK; Gadgaard S; Kizilkaya HS; Willems S; Zhong Y; Wang Y; Wright SC; Lauschke VM; Hartmann B; Holst JJ; Selent J; Rosenkilde MM
    Br J Pharmacol; 2024 Jul; ():. PubMed ID: 38952084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model.
    Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ
    Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
    Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
    Sparre-Ulrich AH; Hansen LS; Svendsen B; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Jan; 173(1):27-38. PubMed ID: 26359804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
    Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
    J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling.
    Malde AK; Srivastava SS; Coutinho EC
    J Pept Sci; 2007 May; 13(5):287-300. PubMed ID: 17437246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.
    Tseng CC; Kieffer TJ; Jarboe LA; Usdin TB; Wolfe MM
    J Clin Invest; 1996 Dec; 98(11):2440-5. PubMed ID: 8958204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling.
    Tseng CC; Zhang XY
    Endocrinology; 2000 Mar; 141(3):947-52. PubMed ID: 10698169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes.
    Nie Y; Ma RC; Chan JC; Xu H; Xu G
    FASEB J; 2012 Jun; 26(6):2383-93. PubMed ID: 22366643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.
    Deacon CF; Plamboeck A; Rosenkilde MM; de Heer J; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E468-75. PubMed ID: 16608883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
    Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
    Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
    Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
    J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.